Adjuvant Systemic Treatment of Premenopausal Women With Hormone Receptor-Positive Early Breast Cancer: Lights and Shadows

J Clin Oncol. 2019 Apr 10;37(11):862-866. doi: 10.1200/JCO.18.02433. Epub 2019 Feb 27.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Age Factors
  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / adverse effects
  • Biomarkers, Tumor / analysis*
  • Breast Neoplasms / chemistry
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / pathology
  • Breast Neoplasms / physiopathology
  • Chemotherapy, Adjuvant
  • Clinical Trials as Topic
  • Female
  • Humans
  • Neoplasm Recurrence, Local
  • Ovary / drug effects*
  • Ovary / physiopathology
  • Premenopause*
  • Receptor, ErbB-2 / analysis*
  • Receptors, Estrogen / analysis*
  • Receptors, Progesterone / analysis*
  • Risk Assessment
  • Risk Factors
  • Time Factors
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Biomarkers, Tumor
  • Receptors, Estrogen
  • Receptors, Progesterone
  • ERBB2 protein, human
  • Receptor, ErbB-2